Blog

New Research on 1911 Gold Corporation (TSX-V: AUMB | OTCQX: AUMBF)

karen@crystalra.com (Karen Goldfarb) — Fri, 29 May 2026 17:05:41 GMT

A new Executive Informational Overview is now available on 1911 Gold Corporation (TSX-V: AUMB | OTCQX: AUMBF), a Canadian gold explorer and developer focused on restarting the True North Gold Project in Manitoba’s Rice Lake greenstone belt. The Company controls the fully permitted True North mine, mill, and tailings facility, along with a 61,647-hectare land package that includes the Ogama-Rockland Gold Deposit and several past-producing mines. This 56-page report explores 1911 Gold's business model, growth strategy, market opportunity, competitive landscape, and key risks. Download the full report below.

Snapshot

1911 Gold Corporation (“1911 Gold” or “the Company”) is a Canadian-based gold explorer and developer focused on the restart and advancement of its assets in Manitoba’s Rice Lake greenstone belt. The Company’s principal asset is the True North Gold Project (“True North”), with fully permitted infrastructure, including the True North mine and mill complex, and the tailings management facility (the “True North Complex”). 1911 Gold also controls a 61,647-hectare land package in and around the mine area, covering a significant portion of the Archean Rice Lake greenstone belt, which contains the Ogama-Rockland Gold Deposit (“Ogama-Rockland”), along with several past-producing mines. The True North mine is an inactive underground operation with a production history dating back to 1927. The Company was formed following the 2018 transfer of the True North Gold Project and related Canadian assets from Klondex Mines Ltd to Havilah Mining Corporation, which was renamed 1911 Gold Corporation in 2019.

Key Points of 1911 Gold Corporation

1911 Gold controls the fully permitted True North mine, mill, and infrastructure package in Manitoba, including a 1,350 tonnes per day centralized processing facility that is readily expandable.
The Company is advancing a historically productive, district-scale asset base anchored by the True North Complex and several past-producing mines. This history supports both the district’s geological credibility and the Company’s hub-and-spoke† growth strategy.
1911 Gold’s 2024 1.1 million ounce gold resource provides the technical foundation for the planned 2027 restart at True North. Located within the fully permitted mine lease area, the resource includes 499,000 Indicated ounces at 4.41 g/t Au and 644,000 Inferred ounces at 3.65 g/t Au, with potential for further growth and expansion across the broader district.
The Company’s restart strategy includes 2026 test mining to evaluate measures aimed at limiting dilution, including right-sized development and equipment, tighter grade control, and improved mine planning to address historical mining method and execution challenges.
1911 Gold’s profile has strengthened alongside growing recognition of the True North restart opportunity, supported by its 2026 TSX Venture 50™ recognition, fourth overall ranking, and upgrade to the OTCQX market to broaden U.S. investor access.
At December 31, 2025, 1911 Gold reported C$23.6 million in cash and cash equivalents and C$14.5 million in working capital. Liquidity improved further after year-end with the initial US$15 million draw under its US$30 million secured Auramet credit facility in March 2026.

*******************************************

Listen to our newest podcast 🎙️on 1911 Gold Corp.:

1911 Gold: Reviving Manitoba’s Historic Gold Camps

Click below to view our most recent company podcasts.

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on 1911 Gold Corp.

*******************************************

May 2026 Update on BacTech Environmental Corp. (CSE: BAC | OTCQB: BCCEF | FSE: 0BT1)

karen@crystalra.com (Karen Goldfarb) — Tue, 26 May 2026 16:23:42 GMT

Crystal Research Associates has issued a 10-page Company Update on BacTech Environmental Corporation
(CSE: BAC | OTCQB: BCCEF | FSE: 0BT1) following the release of their recent news and financial results.

Snapshot

BacTech Environmental Corporation (“BacTech” or “the Company”) is a Canadian-based cleantech company that has spent more than three decades developing and applying bioleaching to difficult mineral concentrates and mine waste. Management describes the business as “our bugs eat rocks,” reflecting the use of naturally occurring bacteria to oxidize sulphide minerals, liberate metals, and neutralize harmful toxins, such as arsenic, in an atmospheric, water-based process. Using its proprietary BACOX® bioleaching technology, BacTech targets arsenic-rich concentrates and tailings (finely ground mine waste left after mineral extraction), converting long-standing environmental liabilities into stable, saleable products. The Company has built three commercial bioleach plants for gold under prior licensing arrangements in Western Australia, Tasmania, and China, and is now advancing an owner-operated bioleach facility in the Tenguel-Ponce Enríquez region of Ecuador, focused on refractory gold concentrates and arsenic-bearing materials. In parallel, BacTech is developing its patent-pending “Zero Tailings™” process, the Company’s initiative to treat historic tailings, recover metal values and co-products such as iron and sulphur, and leave behind inert silica (sand), with the goal of building a network of modular bioleaching and zero tailings facilities that can clean up legacy mining waste while generating solid economic returns.

Key Points of BacTech Environmental Corporation

BacTech’s core opportunity is built around converting difficult-to-treat mining materials into saleable products while reducing long-term environmental liabilities. Its BACOX® bioleaching technology targets arsenic-rich concentrates, including through the Company’s planned Tenguel project in Ecuador, while its Zero Tailings™ platform is designed to recover critical minerals, magnetite, fertilizer, and silica from legacy tailings.
During the quarter, BacTech strengthened its Zero Tailings™ IP position through national patent filings in Canada and the U.S., followed by a May 2026 provisional patent upgrade adding reverse osmosis pre-concentration and mechanical vapour recompression evaporation to the flowsheet. The enhancement is intended to improve the economics of producing specification-grade ammonium sulphate fertilizer from dilute mining-derived streams and broaden the technology’s potential licensing market across hydrometallurgical operations.
BacTech is advancing its planned Tenguel bioleach facility and Zero Tailings™ platform from development toward commercialization. Key milestones are expected to include securing project-level financing for Tenguel and continued validation of the Sudbury Zero Tailings™ flowsheet as the Company seeks to scale its bioleaching and mine-waste remediation strategy.
BacTech reported a net loss and comprehensive loss of C$1.8 million for 2025, compared with C$0.8 million in 2024, while total liabilities declined to C$3.2 million from C$4.8 million following financing activity and the settlement of convertible debenture obligations. At year-end, the Company had C$19,425 in cash and C$372,500 in marketable securities.
BacTech’s leadership and technical team have decades of bioleaching and project-development experience, supported by research relationships such as MIRARCO in Sudbury. These capabilities strengthen the Company’s ability to advance its technology from pilot work toward commercial deployment.

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on BacTech Environmental Corporation

*******************************************

April 2026 Update on Banzai International, Inc. (BNZI-NASDAQ)

karen@crystalra.com (Karen Goldfarb) — Tue, 21 Apr 2026 19:27:46 GMT

Crystal Research Associates has issued an 11-page Company Update on MarTech company, Banzai International, Inc. (BNZI-NASDAQ) following the release of their fourth quarter and year-end financial results.

Snapshot

Banzai International, Inc. (“Banzai” or “the Company”) is a dynamic innovator in the marketing technology (MarTech) sector, leveraging data-driven solutions to empower businesses across diverse industries. The Company offers Software as a Service (SaaS), Artificial Intelligence (AI)-enabled marketing, and sales applications for businesses of all sizes. Banzai is building a comprehensive integrated platform to provide its clients with a complete streamlined product suite that communicates seamlessly with all facets of their marketing and sales operations under a unified architecture. The Company’s business model emphasizes cost-effective customer acquisition, new product introduction, and profitability. Banzai’s customer acquisition is based on a “Land and Expand” growth model, encouraging customers to start with one product and adopt more of the Company’s products over time, supported by an integrated suite that delivers a unified user experience. Its product roadmap includes both internal development and acquisitions. Internally, the Company identifies unmet customer needs to guide development. On the acquisition front, it targets profitable businesses with high-growth potential that expand its platform’s functionality. Banzai has strategically positioned itself at the forefront of the AI-driven MarTech sector, integrating AI-enabled functionalities across its platform to deliver predictive analytics, content creation, and automated workflows. The Company’s product offerings support the entire marketing funnel, from lead capture to engagement and analytics. This integrated approach aligns with the growing market demand for centralized, efficient marketing solutions, with 60% of marketers now preferring all-in-one solutions over separate specialized tools due to integration challenges.

Key Points of Banzai International, Inc.

Banzai reported fourth quarter and year end 2025 financial results. Full year revenue grew 169% to $12.2 million and gross profit of $10.0 million, up from $3.1 million in the prior year, resulting in gross margin expansion to 82.0% from 68.6%. Net loss improved by $9.0 million, or 29%, to $22.5 million for the year ended December 31, 2025, versus $31.5 million in 2024. In 4Q 2025, revenue increased 116% year over year to $2.8 million, while gross profit rose to $2.3 million, gross margin improved to 81.9% from 71.3%, and net loss narrowed 36% to $5.0 million.
In March 2026, the Company announced that it has reached an agreement to acquire assets of ConnectAndSell, Inc., a profitable AI-powered sales enablement platform serving B2B organizations across financial services, healthcare, technology, and other industries. This follows the November 7, 2025, closing of the Company’s acquisition of privately-held Superblocks, an Agentic AI platform for developing and hosting launch-ready SEO-optimized websites.
In October 2025, the Company executed a debt conversion agreement with CP BF Lending, LLC for the remaining principal balance of its outstanding senior secured debt, totaling approximately $4.8 million. This continues Banzai’s debt elimination initiatives aimed at fortifying its capital structure and balance sheet positions.
Banzai announced that an institutional investor increased a direct equity stake to 18.7% following the exercise of warrants given as consideration of the ClearDoc, Inc. acquisition, demonstrating their continued confidence in Banzai’s long-term strategy.
As of December 31, 2025, Banzai’s cash position stood at $0.3 million, compared to $1.1 million at year-end 2024. Subsequent to December 31, 2025, the Company issued shares under its ATM Agreement for net proceeds of approximately $1.3 million.

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on Banzai International, Inc.

*******************************************

New Research on Atlas Salt Inc. (TSXV:SALT | OTCQX:SALQF)

karen@crystalra.com (Karen Goldfarb) — Tue, 17 Feb 2026 15:56:26 GMT

A new Executive Informational Overview is now available on Atlas Salt Inc. (TSXV:SALT | OTCQX:SALQF), a Canada-based industrial minerals developer in Newfoundland and Labrador advancing the Great Atlantic Salt Project in Western Newfoundland to supply de-icing salt to Eastern Canada and the U.S. Northeast. This 45-page report explores Atlas Salt's business model, growth strategy, market opportunity, competitive landscape, and key risks. Download the full report below.

Snapshot

Atlas Salt Inc. (“Atlas” or “the Company”) is a Canada-based industrial minerals developer headquartered in Newfoundland and Labrador. The Company is advancing the Great Atlantic Salt Project (“Great Atlantic” or “the Project”) in the St. George’s Bay Basin in Western Newfoundland, with plans for a conventional underground mine aimed at supplying de-icing salt to customers in Eastern Canada and the U.S. Northeast. The site is roughly 2 km from the Turf Point deepwater port and about 1.4 km from the St. George’s substation, with the Trans-Canada Highway running nearby, which are all central to the Project’s logistics plan. Great Atlantic is expected to be North America’s first new salt mine in nearly three decades. The project received a conditional release from the provincial environmental assessment (EA) process in April 2024, and in July 2025, the province approved an Early Works Development Plan supporting defined site preparation activities. In September 2025, Atlas published an Updated Feasibility Study (UFS) that lays out the base development plan: a 4.0 million tonne per annum (Mtpa) mine over a 24.3-year operating life, with after-tax economics of C$920 million NPV (8% discount rate) and a 21.3% IRR (per the UFS).

Key Points of Atlas Salt Inc.

Atlas is targeting the North American road salt market, which management describes as import-reliant, with a focus on delivered cost and supply reliability.
The global salt market was valued at ~$26.9 billion in 2025 and is forecast to reach ~$39.4 billion by 2034 (4.4% CAGR); Fortune Business Insights cites chemical processing and de-icing among key demand drivers, with de-icing-grade rock salt representing Great Atlantic’s intended focus.
Great Atlantic is backed by a large, high-purity reserve base (probable reserves of ~95 Mt at ~95.9% NaCl), with additional drill defined resource of 868 Mt allowing for the potential for mine life and throughput to expand over time.
Atlas cites a logistics advantage into Eastern Canada and the U.S. Northeast (<3 days to Boston versus >14 days from Egypt/Chile) and access to hydro power as part of its lower-emissions positioning.
The Company has begun lining up key counterparties via non-binding Memorandum of Understandings (MOUs), including Scotwood Industries (packaged-salt offtake), Sandvik (equipment support/financing), and Hatch (engineering partner).
The near-term path is execution-driven: obtain remaining permits, secure additional offtakes/partnerships, and finalize a financing package ahead of construction, with production targeted around 2030.
Management is build-and-finance oriented, with experience across underground mine construction, large-scale project delivery, and mining capital markets, supported by a Board that includes salt-relevant operating experience.
As of mid-Q4, Atlas reported C$10.4 million of net cash following its October 2025 financing. The Company has no general warrant overhang, other than broker compensation warrants.r.

*******************************************

Listen to our newest podcast 🎙️on Atlas Salt:

How_Atlas_Salt_Solves_The_Salt_Deficit

Click below to view our most recent company podcasts.

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on Atlas Salt Inc.

*******************************************

New Research on OS Therapies Inc. (NYSE American: OSTX)

karen@crystalra.com (Karen Goldfarb) — Fri, 09 Jan 2026 18:29:59 GMT

A new Executive Informational Overview is now available on OS Therapies Inc. (NYSE American: OSTX), a clinical-stage cancer immunotherapy company developing treatments for osteosarcoma and other solid tumors. Its lead program, OST-HER2, targets HER2-expressing cancers and has shown positive Phase 2b results in lung-metastatic osteosarcoma, alongside a broader pipeline built on two proprietary platforms. This 62-page report explores OS Therapies' business model, growth strategy, market opportunity, competitive landscape, and key risks. Download the full report below.

Snapshot

OS Therapies Inc. (“OS Therapies” or “the Company”) is a clinical-stage cancer immunotherapy company focused on discovering, developing, and commercializing treatments for osteosarcoma and other solid tumors. The Company has built a diversified pipeline around two novel technology platforms: OST-Lm, a bioengineered form of Listeria monocytogenes designed to drive robust immune responses against HER2-expressing cancer cells; and OST-tADC, a next-generation tunable antibody-drug conjugate platform. The lead OST-Lm program, OST-HER2, is in clinical development for osteosarcoma and breast cancer and holds conditional approval for canine osteosarcoma. A Phase 2b clinical trial in resected lung-metastatic osteosarcoma has completed its treatment phase and has demonstrated statistically significant improvements in 12-month Event-Free Survival (EFS) (primary endpoint) and overall survival (OS) (secondary endpoint), with a favorable safety profile. OS Therapies’ pipeline also includes multiple mid- and early-stage assets—OST-AXAL (HPV-related cancers), OST-503 (NSCLC and glioblastoma), and OST-504/PSA (prostate cancer)—along with additional preclinical programs targeting more than 30 solid tumor types. OS Therapies is also advancing its proprietary OST-tADC platform, currently in pre-clinical development. The Company is initially assessing the use of this platform on ovarian and breast cancer. The Company established a subsidiary, OS Drug Conjugates, to develop the OST-tADC platform internally and pursue licensing and partnership opportunities.

Key Points of OS Therapies Inc.

OST-HER2 received the FDA’s rare pediatric disease designation (RPDD), together with orphan drug and fast track designations from the FDA and the EMA for its osteosarcoma program. Its RPDD makes it eligible for a Priority Review Voucher (PRV), which the Company plans to sell.
OST-HER2’s Phase 2b osteosarcoma trial met its primary endpoint, achieving a 35% 12-month EFS rate versus roughly 20% in historical controls. Interim two-year assessments of the secondary endpoint (three-year OS) were also positive, with 75% of patients still alive versus about 40% in historical controls.
OS Therapies intends to submit a Biologics License Application (BLA) for OST-HER2 in osteosarcoma by the end of January 2026, aiming for FDA Accelerated Approval in Q3 2026. The Company intends to submit for conditional Marketing Authorization Application (MAA) to the UK’s MHRA (end of January 2026) and the EMA (end of February 2026).
OS Therapies formed OS Animal Health, Inc., focused on OST-HER2 for canine osteosarcoma. The Company aims to file documentation for a ‘go-public’ transaction in January 2026.
On August 7, 2025, the Company announced that its NYSE listing was included in the Russell Microcap, Russell Microcap Value, and Russell Microcap Growth indexes.
As of September 30, 2025, OS Therapies held $1.876 million in cash, and received an additional $1.5 million after quarter-end, primarily from the previously announced warrant exercise inducement and exchange offer.

*******************************************

Listen to our podcast:

Inside OS Therapies Immunotherapy Data and the Road to Filing

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on OS Therapies Inc.

*******************************************

New Research on BacTech Environmental (CSE:BAC | OTCQB:BCCEF | FSE:0BT1)

karen@crystalra.com (Karen Goldfarb) — Wed, 07 Jan 2026 16:50:14 GMT

A new Executive Informational Overview is now available on BacTech Environmental Corporation (CSE: BAC | OTCQB: BCCEF | FSE: 0BT1), a Canadian cleantech company that uses bioleaching (natural bacteria) to recover metals from arsenic-rich mining waste and historic tailings while reducing environmental risk, with its lead project advancing in Ecuador. This 46-page report explores BacTech's business model, growth strategy, market opportunity, competitive landscape, and key risks. Download the full report below.

Snapshot

BacTech Environmental Corporation (“BacTech” or “the Company”) is a Canadian-based cleantech company that has spent more than three decades developing and applying bioleaching to difficult ore bodies and mine waste. Management describes the business as “our bugs eat rocks,” reflecting the use of naturally occurring bacteria to oxidize sulphide minerals, liberate metals, and neutralize harmful toxins in an atmospheric, water-based process. Using its proprietary BACOX® bioleaching technology, BacTech targets arsenic-rich concentrates and tailings (finely ground mine waste left after mineral extraction), converting long-standing environmental liabilities into stable, saleable products. The Company has built three commercial bioleach plants for gold under prior licensing arrangements in Western Australia, Tasmania, and China, and is now advancing an owner-operated bioleach facility in the Tenguel-Ponce Enríquez region of Ecuador, focused on refractory gold concentrates and arsenic-bearing materials. In parallel, BacTech is developing its patent-pending “Zero Tailings™” process—the Company’s initiative to treat historic tailings to recover metal values from critical minerals and leave behind a more stable, lower-risk residue, with the goal of building a network of modular bioleaching and zero-tailings facilities that can clean up legacy mining waste while generating solid economic returns.

Key Points of BacTech Environmental Corporation

Specialist in “problem” feed bioleaching. As one of only two companies worldwide with commercial bioleaching operations, BacTech is shifting from licensing to owning and operating projects that treat high-arsenic concentrates and different types of tailings.
High-return Tenguel gold project in Ecuador. Tenguel, Ecuador is a fully permitted, high-return gold project. Phase 1 is designed for 50 tonnes-per-day and ~35,000 oz/year for ~$22 million in capex, with modeled revenue of ~$120 million at $3,500/oz and ~1-year payback. Expansion potential could be 250 tonnes-per-day and >100,000 oz/year under a 12-year tax holiday.
Zero Tailings™ growth platform in critical minerals and green iron. BacTech’s patent-pending Zero Tailings™ flowsheet in Sudbury (Sudbury, Ontario) targets pyrrhotite tailings to recover nickel, copper, and cobalt and produce magnetite and ammonium sulphate fertilizer, leaving inert residues for backfill and construction. The program is supported by recent Patent Cooperation Treaty (PCT) and “Zero Waste” patent filings.
Strong Environmental, Social, and Governance (ESG) and green-finance angle. BacTech’s water-based, closed-circuit processes aim to avoid arsenic-bearing off-gas and stabilize arsenic as ferric arsenate, supported by leachability testing and applicable standards. Compared to roasting and pressure oxidation (POX), BacTech’s approach may support green/social financing and carbon-credit benefits.
Catalyst-Driven Story. Key catalysts include securing Tenguel financing, moving into construction and first gold pour, and advancing the Sudbury Zero Tailings™ program.
Near-Term Liquidity. At September 30, 2025, the Company reported cash of C$81,000 and a working capital deficit.

*******************************************

Listen to our podcast:

BacTech Environmental Corporation: Turning Mine Waste Into Profit

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on BacTech Environmental Corporation.

*******************************************

New Research on Kazia Therapeutics Limited (KZIA-NASDAQ)

karen@crystalra.com (Karen Goldfarb) — Sat, 22 Nov 2025 00:37:20 GMT

A new Executive Informational Overview is now available on Kazia Therapeutics Limited (KZIA-NASDAQ), a clinical-stage oncology biotech company advancing two licensed small molecules: paxalisib for glioblastoma and other CNS cancers, and EVT801 for advanced solid tumors, including ovarian cancer. This 60-page report explores Kazia's business model, growth strategy, market opportunity, competitive landscape, and key risks. Download the full report below.

Snapshot

Kazia Therapeutics Limited (“Kazia” or “the Company”) is a Sydney-based clinical-stage oncology company focused on high-need cancers of the central nervous system (CNS) and select hard-to-treat solid tumors. The portfolio includes two small-molecule programs: (1) paxalisib, a brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, a critical signaling route that helps cancer cells grow and multiply, licensed from Genentech, and (2) EVT801, a selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor licensed from Evotec SE. Paxalisib is designed to achieve reliable drug levels in the brain, addressing a central barrier to treatment. It is advancing toward a single pivotal study in newly diagnosed, MGMT-unmethylated glioblastoma (GBM) and is being studied across additional settings, including brain metastases, select gliomas, such as Diffuse Intrinsic Pontine Glioma (DIPG), primary CNS lymphoma, and certain advanced breast cancer subtypes. Paxalisib has secured multiple FDA designations (Orphan Drug, Fast Track, Rare Pediatric Disease), enhancing regulatory engagement speed and providing potential market exclusivity, priority review, and other incentive benefits. EVT801 targets VEGFR3 to limit lymphangiogenesis—the formation of new lymphatic vessels that can enable tumor growth and metastasis—and favorably conditions the tumor microenvironment. Stage 1 of the first-in-human study is complete, with final Phase 1 readout expected in CY2025 and Phase 2 planning underway, initially in high-grade serous ovarian cancer (HGSOC) with potential immunotherapy combinations under evaluation.

Key Points of Kazia Therapeutics Limited

Kazia runs a lean, partnership-first model. The Company outsources manufacturing and early development, focuses its spending on clinical trials, and pursues non-dilutive capital through regional licenses and research collaborations.
Selective deals and collaborations include Simcere (Greater China) and Sovargen (select neurology), with research ties to QIMR Berghofer, Pacific Pediatric Neuro-Oncology Consortium (PNOC), and Memorial Sloan Kettering Cancer Center (MSKCC).
Paxalisib’s composition-of-matter patents run to 2031; with process claims and Patent Term Extension (PTE)/Supplementary Protection Certificate (SPC) protection potentially to 2036 in major markets.
Kazia’s leadership has been strengthened with CEO Dr. John Friend and Chairman Bryce Carmine, who bring clinical, operational, and market expertise to support the next phase of development.
As of December 31, 2024, the Company’s cash position was ~A$3.06 million. Since then, Kazia raised $2 million via a registered direct (January 10, 2025), received $1 million from the Cantrixil IP sale (March 30, 2025), and closed a $2 million premium private placement (August 1, 2025), supporting flexible dilutive and non-dilutive funding as late-stage studies advance.

*******************************************

Listen to our podcast:

Kazia Therapeutics: Paxalisib and EVT801 Oncology Pipeline Overview

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on Kazia Therapeutics Limited

*******************************************

New Research on Nova Minerals, Ltd. (NVA-NASDAQ)/(NVA-ASX)

karen@crystalra.com (Karen Goldfarb) — Wed, 19 Nov 2025 14:05:10 GMT

A new Executive Informational Overview is now available on Nova Minerals, Ltd. (NVA-NASDAQ)/(NVA-ASX), a gold, antimony, and critical minerals exploration and development company focused on advancing its flagship Estelle Project in Alaska, where it holds an 85% interest. This 66-page report explores Nova's business model, growth strategy, market opportunity, competitive landscape, and key risks. Download the full report below.

Snapshot

Nova Minerals Limited (“Nova” or “the Company”) is a gold, antimony, and critical minerals exploration and development company focused on advancing its flagship Estelle Project in Alaska, where it holds an 85% interest. Estelle sits on mining-friendly, state-owned land in the prolific Tintina Gold Belt. The district-scale project spans 514 km² and hosts more than 20 gold and antimony prospects. Its two main gold deposits, Korbel and RPM, support a JORC-compliant resource of 9.9 million ounces of gold, making Estelle one of the largest undeveloped gold projects globally. The region also has a long history of antimony production. Nova is prioritizing seven gold-antimony prospects for near-term evaluation and development, led by Stibium and Styx, where stibnite is exposed at surface. Backed by strong federal, state, and local support, and with the U.S. Department of War recognizing the strategic value of Nova’s antimony assets, the Company is executing a dual-commodity strategy. It is advancing its gold assets toward tier-one scale while using the US$43.4 million U.S. Department of War award to build a fully domestic, integrated antimony supply chain in the U.S., targeting military-grade production in 2026/2027. The Company trades on both the NASDAQ and Australian Stock Exchange (ASX).

Key Points of Nova Minerals Ltd.

Gold and antimony prices have reached record highs during 2025, with gold exceeding US$4,000/oz for the first time and antimony prices rising to nearly US$63,000/ton, more than quadrupling since early 2024.
Estelle is among the largest undeveloped gold projects globally. In 2025, Nova is drilling to advance the RPM and Korbel deposits toward feasibility and permitting. The project has also been independently identified as one of only nine worldwide—and just two in the U.S.—with near-term antimony production potential, positioning Nova to help reduce U.S. reliance on foreign supply.
A 2023 JORC compliant scoping study yielded an estimated pre-tax NPV of US$654 million, and an IRR of ~53%. Of note, the study focused on only the three gold locations, without considering antimony operations, and used a base gold price of US$1,850/oz. With gold recently surpassing US$4,000/oz in October 2025, the project’s outlook has significantly improved.
Nova was awarded US$43.4 million in funding from the U.S. Department of War (formerly the Department of Defense) to onshore a domestic U.S. supply chain for the critical mineral antimony based in Alaska.
Nova is led by an experienced management team with a history of advancing resource projects into production, and who have collectively invested over US$5 million in the Company.
By quarter-end September 2025, Nova had over A$86.3 million available: A$17.5 million in cash, a US$43.4 million (A$65.5 million) 24-month U.S. Department of War award for Alaska antimony, and about A$3.3 million in liquid investments and in-the-money warrants, with no debt.

*******************************************

Listen to our podcast:

Nova Minerals: Inside Alaska’s Gold and Antimony Strategy

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on Nova Minerals Ltd.

*******************************************

November 2025 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

karen@crystalra.com (Karen Goldfarb) — Mon, 17 Nov 2025 17:46:09 GMT

Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Snapshot of GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing multi-antigen vaccines for infectious diseases and gene-directed therapies for solid tumors. Its lead program, GEO-CM04S1, is an MVA-based COVID-19 vaccine designed to provide broader, more durable protection, particularly for immunocompromised patients who remain underserved by current mRNA vaccines. GEO-CM04S1 is in multiple Phase 2 trials as a primary vaccine in immunocompromised patients (including those with hematologic malignancies or post-transplant status) and as a booster in both patients with chronic lymphocytic leukemia (CLL) and healthy adults previously vaccinated with mRNA vaccines. In oncology, the Company’s lead asset is Gedeptin®, a gene-directed enzyme prodrug therapy that has completed a multicenter Phase 1/2 trial in advanced head and neck cancers, with a Phase 2 neoadjuvant trial (AdPNP-203) in preparation that will evaluate intra-tumoral Gedeptin with intravenous fludarabine and neoadjuvant pembrolizumab, alongside expanded preclinical work in additional solid tumors. GeoVax is also advancing GEO-MVA, a Mpox and smallpox vaccine candidate that, based on favorable European Medicines Agency advice, is expected to move directly into a single Phase 3 immunobridging trial. Supported by worldwide rights, a growing intellectual property portfolio, and scalable manufacturing plans, including a shift from egg-based to modern cell line platforms, GeoVax is led by an experienced management team focused on high-impact vaccines and immunotherapies for urgent, underserved medical needs.

Key Points

On November 13, 2025, GeoVax reported a Q3 2025 net loss of $6.3 million ($0.31 per share) versus $5.8 million ($0.91 per share) in Q3 2024. The Company ended the quarter with $5.0 million in cash.
Phase 2 trials of GEO-CM04S1 in immunocompromised and CLL patients continue to show strong T-cell and antibody responses, no serious vaccine-related adverse events, and achievement of the CLL trial’s primary immunogenicity endpoint.
GEO-MVA advanced along an EMA-endorsed pathway in which a single Phase 3 immunobridging trial is expected to support centralized EU marketing authorization, with WHO’s reaffirmation of Mpox as a global emergency and reinforcing the need for additional MVA-based vaccine supply.
Gedeptin® is being advanced into AdPNP-203, a Phase 2 neoadjuvant trial in resectable head and neck squamous cell carcinoma (Gedeptin + fludarabine + neoadjuvant pembrolizumab), with preclinical work expanding into triple-negative breast and cutaneous malignancies.
GeoVax reinforced its role as a U.S.-based “Made-in-America” MVA vaccine developer, highlighting continuous avian cell-line manufacturing, alignment with U.S. biodefense and onshoring priorities, and active engagement with U.S. and global health agencies.
The Company’s IP portfolio includes a June 2025 U.S. patent on a novel MVA-based malaria vaccine construct and more than 135 patents across 23 families supporting its multi-antigen infectious disease and oncology platform.
.

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

New Research on Agroz Inc. (AGRZ-NASDAQ)

karen@crystalra.com (Karen Goldfarb) — Mon, 10 Nov 2025 13:18:12 GMT

A new Executive Informational Summary is now available on Agroz Inc., a Malaysia-based AgTech company that designs and operates climate-controlled vertical farms producing clean, year-round vegetables. This 24-page report explores Agroz's business model, growth strategy, market opportunity, competitive landscape, and key risks. Download the full report below.

Snapshot

Agroz Inc. is a vertically integrated agricultural technology (AgTech) company pioneering the future of food production through scalable indoor vertical farming and AI-powered farm management systems. Headquartered in Malaysia, the Company designs, builds, and operates climate-controlled farms that produce clean, pesticide-free vegetables year-round. Its proprietary Agroz Operating System (Agroz OS) and Agroz Copilot AI platform optimize every aspect of crop growth, energy use, and supply chain efficiency. With partnerships that include Microsoft and distribution through leading retailers, such as AEON and Village Grocer, Agroz is positioned at the forefront of the AgTech revolution in Southeast Asia and beyond.

Key Points of Agroz Inc.

AI-Powered Vertical Farming Platform. Agroz combines its proprietary Agroz OS and Copilot AI assistant to automate vertical farming, from environmental controls to predictive crop analytics, delivering scalable efficiency and consistent high-quality yields.
Multiple Revenue Streams with Recurring Potential. The Company earns revenue through the design, construction, and sale of vertical farms; third-party farm management through the use of its Agroz OS; produce sales; and SaaS software licensing, creating a diversified model with strong recurring potential.
Strategic Retail and Technology Partnerships. Agroz distributes through major grocers like AEON and Village Grocer and is a Microsoft AI Cloud and ISV partner, boosting its market access and software credibility.
Strong ESG and Urban Infrastructure Fit. Its modular, pesticide-free farms are well-suited to urban environments, supporting sustainable, localized food production with lower carbon footprints.
IPO-Backed Expansion into High-Growth Markets. Agroz sold 1,250,000 shares at $4.00 in its IPO and began trading on NASDAQ on October 1, 2025 as AGRZ. Proceeds will fund expansion in ASEAN and MENA, including Indonesia, Thailand, and the UAE, where food import reliance and urban demand are rising.
Cash and Liquidity. As of December 31, 2024, Agroz reported ~US$85,000 in cash and short-term investments. On October 3, 2025, the Company completed a NASDAQ IPO raising roughly US$5 million, improving near-term liquidity and funding expansion.

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on Agroz Inc.

*******************************************

Listen to our podcast:

Agroz's Vertical Farm AI Copilot: Can Generative AI and a $5 million IPO Solve Global Food Security?

*******************************************